Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse

BACKGROUND: Ibrutinib, an irreversible Bruton Tyrosine Kinase (BTK) inhibitor, has revolutionized Chronic Lymphocytic Leukemia (CLL) treatment, but resistances to ibrutinib have emerged, whether related or not to BTK mutations. Patterns of CLL evolution under ibrutinib therapy are well characterized...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Biomark Res
Huvudupphovsmän: Cadot, Sarah, Valle, Carine, Tosolini, Marie, Pont, Frederic, Largeaud, Laetitia, Laurent, Camille, Fournie, Jean Jacques, Ysebaert, Loic, Quillet-Mary, Anne
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2020
Ämnen:
Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724843/
https://ncbi.nlm.nih.gov/pubmed/33298182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00253-w
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk